Antitumor activity of the 16-kDa prolactin fragment in prostate cancer.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Cancer Research

• Publication date

  2003-01-15

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 12543792
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer

  2001cited by this paper
• Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice.

  2001cited by this paper
• Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway.

  2001cited by this paper
• A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

  2001cited by this paper
• Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer.

  2001cited by this paper
• Clinical studies of angiogenesis inhibitors: The university of texas md anderson center trial of human endostatin

  2001cited by this paper
• Gene therapy for prostate cancer: where are we now?

  2000cited by this paper
• TNP-470: an angiogenesis inhibitor in clinical development for cancer

  2000cited by this paper
• The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation.

  2000cited by this paper
• Inhibition of rat corneal angiogenesis by 16-kDa prolactin and by endogenous prolactin-like molecules.

  1999cited by this paper
• Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis.

  1999influential reference
• Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions.

  1999cited by this paper
• Effects of angiogenesis inhibitors on multistage carcinogenesis in mice.

  1999cited by this paper
• Pharmacokinetics of thalidomide in an elderly prostate cancer population.

  1999cited by this paper
• Tumor-suppressive activity of CD66a in prostate cancer

  1999cited by this paper
• Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice.

  1998cited by this paper
• Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland.

  1998cited by this paper
• Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression.

  1998cited by this paper
• Neuroendocrine and reproductive functions in male mice with targeted disruption of the prolactin gene.

  1998cited by this paper
• Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in gleason sum 5 to 7 adenocarcinoma of the prostate

  1997cited by this paper
• Prolactin and prolactin receptors are expressed and functioning in human prostate.

  1997influential reference
• SAS System for Mixed Models

  1996cited by this paper
• Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects.

  1996cited by this paper
• Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study.

  1995cited by this paper
• Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin.

  1995cited by this paper
• Structural variants of prolactin: occurrence and physiological significance.

  1995cited by this paper
• Angiogenesis in cancer, vascular, rheumatoid and other disease

  1995cited by this paper
• Effect of prolactin on the prostate

  1994cited by this paper
• Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma.

  1994cited by this paper
• The Relationship of Angiogenesis to Biological Activity in Human Squamous Cell Carcinomas of the Head and Neck

  1994cited by this paper
• Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity

  1994cited by this paper
• Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis.

  1993influential reference
• Mass spectrometric analysis of the fragments produced by cleavage and reduction of rat prolactin: evidence that the cleaving enzyme is cathepsin D.

  1993influential reference
• The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis.

  1993influential reference
• Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.

  1993cited by this paper
• Comparison of microscopic vascularity in benign and malignant prostate tissue.

  1993cited by this paper
• Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer.

  1992cited by this paper
• Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma.

  1992cited by this paper
• Prolactin gene expression in human thymocytes.

  1992cited by this paper
• A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells.

  1992cited by this paper
• Relation of neovascularisation to metastasis of non-small-cell lung cancer.

  1992cited by this paper
• Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.

  1991cited by this paper
• The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells.

  1991cited by this paper
• The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study.

  1988cited by this paper
• Analysis of the proteolytic cleavage of prolactin by the mammary gland and liver of the rat: characterization of the cleaved and 16K forms.

  1987cited by this paper
• Phosphorylation of prolactin.

  1986cited by this paper
• Proteolytic modification of rat prolactin by subcellular fractions of the lactating rat mammary gland.

  1986cited by this paper
• Neovascularization in human cutaneous melanoma: a quantitative morphological and Doppler ultrasound study.

  1986cited by this paper
• Cleaved prolactin: evidence for its occurrence in human pituitary gland and plasma.

  1985cited by this paper
• Glycosylated human prolactin.

  1985cited by this paper
• Glycosylated ovine prolactin.

  1984cited by this paper
• A cleaved form of prolactin in the mouse pituitary gland: identification and comparison of in vitro synthesis and release in strains with high and low incidences of mammary tumors.

  1984cited by this paper
• Proteolytic degradation and modification of rat prolactin by subcellular fractions of the rat ventral prostate gland.

  1984cited by this paper
• Proteolytic fragmentation of rat prolactin by the rat ventral prostate gland

  1983cited by this paper
• Human prolactin. cDNA structural analysis and evolutionary comparisons.

  1981cited by this paper
• Polypeptide hormones and the prostate.

  1981cited by this paper
• Some experimental results with prolactin: an overview of effects on the prostate.

  1981cited by this paper
• Some experimental results with prolactin: an overview of effects on the prostate.

  1981cited by this paper
• The significance of atypical vessels and neovascularization in cervical neoplasia.

  1981cited by this paper
• Polypeptide hormones and the prostate.

  1981cited by this paper
• The role of prolactin in the growth of the prostate gland.

  1981cited by this paper
• The role of prolactin in the growth of the prostate gland.

  1981cited by this paper
• A novel "cleaved prolactin" in the rat pituitary: part I. Biosynthesis, characterization and regulatory control.

  1980cited by this paper
• Angiogenic Activity as a Marker of Neoplastic and Preneoplastic Lesions of the Human Bladder

  1980cited by this paper
• Establishment and characterization of a human prostatic carcinoma cell line (PC-3).

  1979cited by this paper
• Angiogenesis as a marker of preneoplastic lesions of the human breast

  1978cited by this paper
• Isolation of a human prostate carcinoma cell line (DU 145)

  1978cited by this paper
• Evidence for a role of prolactin in prostate and seminal vesicle growth in immature male rats.

  1977cited by this paper
• Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative.

  1972cited by this paper
• PITUITARY FACTORS INFLUENCING GROWTH OF THE PROSTATE.

  1963cited by this paper
• Synergistic Role of Prolactin in Response of Male Rat Sex Accessories to Androgen.∗

  1957cited by this paper

• The antiangiogenic peptide VIAN-c4551 inhibits lung melanoma metastasis in mice by reducing pulmonary vascular permeability

  2025cites this paper
• Mass Spectrometric and Immunologic Detection of Prolactin-Derived Vasoinhibin in Human Serum.

  2024cites this paper
• Homeostatic Regulation of Pro-Angiogenic and Anti-Angiogenic Proteins via Hedgehog, Notch Grid, and Ephrin Signaling in Tibial Dyschondroplasia

  2023cites this paper
• The 14-Kilodalton Human Growth Hormone Fragment a Potent Inhibitor of Angiogenesis and Tumor Metastasis

  2023cites this paper
• The HGR motif is the antiangiogenic determinant of vasoinhibin: implications for a therapeutic orally active oligopeptide

  2021cites this paper
• Sequence optimization and glycosylation of vasoinhibin: Pitfalls of recombinant production.

  2019cites this paper
• Human Prolactin Point Mutations and Their Projected Effect on Vasoinhibin Generation and Vasoinhibin-Related Diseases

  2017cites this paper
• New insights in prolactin: pathological implications

  2015cites this paper
• PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin

  2014cites this paper
• Characterization of Δ7/11, a functional prolactin-binding protein.

  2012cites this paper
• The angiostatic protein 16K human prolactin significantly prevents tumor-induced lymphangiogenesis by affecting lymphatic endothelial cells.

  2011cites this paper
• Vasoinhibin gene transfer by adenoassociated virus type 2 protects against VEGF- and diabetes-induced retinal vasopermeability.

  2011cites this paper
• The Antiangiogenic 16K Prolactin Impairs Functional Tumor Neovascularization by Inhibiting Vessel Maturation

  2011cites this paper
• Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis

  2010cites this paper
• [Prolactin and its cleaved 16 kDa fragment].

  2010cites this paper
• 16-kDa Prolactin Reduces Angiogenesis, but Not Growth of Human Breast Cancer Tumors In Vivo

  2010influential citation
• The antiangiogenic factor 16 K hPRL induces caspases-dependent apoptosis by a mechanism that requires activation of NF-κ

  2009cites this paper
• Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth.

  2009cites this paper
• The angiostatic 16 K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via NF-κ B activation

  2009cites this paper
• Peptide hormone regulation of angiogenesis.

  2009cites this paper
• Vasoinhibins: novel inhibitors of ocular angiogenesis.

  2008cites this paper
• Role of Prolactin and Vasoinhibins in the Regulation of Vascular Function in Mammary Gland

  2008cites this paper
• 16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1-Rac1-Pak1 signaling pathway.

  2007cites this paper
• A Two-Stage Binomial Test Approach of Gene Identification in Oligonucleotide Arrays

  2007cites this paper
• Anti-angiogenic gene therapy of cancer: current status and future prospects.

  2007cites this paper
• Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL.

  2007cites this paper
• The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation.

  2007cites this paper
• Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer

  2006cites this paper
• Vasoinhibins: endogenous regulators of angiogenesis and vascular function.

  2006cites this paper
• Prolactin/growth hormone–derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis

  2006cites this paper
• The Short Prolactin Receptor Predominates in Endothelial Cells of Micro- and Macrovascular Origin

  2006cites this paper
• Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin

  2006cites this paper
• Opposite Association of Serum Prolactin and Survival in Patients with Colon and Rectal Carcinomas: Influence of Preoperative Radiotherapy

  2006cites this paper
• The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G0-G1 and the G2-M phases.

  2005cites this paper
• 16-kDa prolactin down-regulates inducible nitric oxide synthase expression through inhibition of the signal transducer and activator of transcription 1/IFN regulatory factor-1 pathway.

  2005cites this paper
• Gene selection for oligonucleotide array: an approach using PM probe level data

  2004cites this paper
• Antiangiogenic gene therapy of cancer: recent developments

  2004cites this paper
• Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: study of their antiangiogenic properties and physiological relevance.

  2004influential citation
• Prolactin and the prolactin receptor: new targets of an old hormone

  2004cites this paper
• The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB.

  2003cites this paper
• Current progress in adenovirus mediated gene therapy for patients with prostate carcinoma

  2003cites this paper
• Development of Improved Microarry Gene Expression Indexes using the Probe-level Intensities

  2002cites this paper